NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Grant MD, Marbella A, Wang AT, et al. Menopausal Symptoms: Comparative Effectiveness of Therapies [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2015 Mar. (Comparative Effectiveness Reviews, No. 147.)
Table N-17Sleep disturbance outcomes by age subgroups
| Trial | Outcome | Subgroup | Treatment | N | Results |
|---|---|---|---|---|---|
| Brunner, 2005, United States | Mean change in WHI sleep score | Age 50-54 with MSVS | Placebo | 157 | 0.53 (SD: 4.6) |
| 0.625 mg CEE | 165 | 1.4 (SD: 4.6)a | |||
| Hays, 2003, United States | Mean change in WHI sleep score | Age 50-54 with MSVS | Placebo | 216 | 0.8 (SD: 4.6) |
| 0.625 mg CEE + 2.5 mg MPA | 255 | 1.8 (SD: 4.8)b | |||
| Rigano, 2001, Italy | Percent reporting no insomniaa | Age 48-50 | Placebo | 75 | 29% |
| 0.05 mg estradiol | 88 | 80% | |||
| Age 51-53 | Placebo | 61 | 46% | ||
| 0.05 mg estradiol | 52 | 62% | |||
| Age 54-56 | Placebo | 55 | 17% | ||
| 0.05 mg estradiol | 31 | 100% | |||
- a
Unclear whether 100% reported insomnia at baseline
CEE: conjugated equine estrogen; MPA: medroxyprogesterone acetate ; MSVS: moderate to severe vasomotor symptoms; WHI: Women’s Health Initiative
- a
difference from placebo: p=0.11
- b
difference from placebo: p=0.02
- Table N-17, Sleep disturbance outcomes by age subgroups - Menopausal Symptoms: C...Table N-17, Sleep disturbance outcomes by age subgroups - Menopausal Symptoms: Comparative Effectiveness of Therapies
- hypothetical protein [Azoarcus sp. KH32C]hypothetical protein [Azoarcus sp. KH32C]gi|505249852|ref|WP_015436954.1|Protein
- Mus musculus 6-phosphogluconolactonase (Pgls), transcript variant 2, mRNAMus musculus 6-phosphogluconolactonase (Pgls), transcript variant 2, mRNAgi|659928104|ref|NM_001294269.1|Nucleotide
- Thrombocytopenia 5Thrombocytopenia 5MedGen
Your browsing activity is empty.
Activity recording is turned off.
See more...